A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: The development of a new logistic regression model

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 1, 1999, Pages 57-65

  Timmerman, Dirk ^a   Bourne, Thomas H ^b   Tailor, Anil ^b   Collins, William P ^b   Verrelst, Herman ^b   Vandenberghe, Kamiel ^b   Vergote, Ignace ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

CA 125; Color Doppler imaging; Logistic regression; Ovarian carcinoma; Ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD FLOW; COLOR ULTRASOUND FLOWMETRY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICS; TRANSVAGINAL ECHOGRAPHY; TUMOR VASCULARIZATION;

EID: 0032863906     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70436-9     Document Type: Article

References (22)

1. 1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-8.
2. 2. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
3. 3. Knapp RC, Jacobs I, Schwartz PE. Clinical perspectives in using CA 125. Contemp Ob Gyn 1996;1-7.
4. 4. Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass: an international multicenter study. Cancer 1994;74:1398-406.
5. 5. Vergote IB, Børmer O, Abeler VM. Evaluation of CA 125 in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987;157: 88-92.
6. 6. Cuckle HS, Wald NJ. Screening for ovarian cancer. In: Miller AB, Chamberlain U, Day NE, Hakama M, Prorok PC, editors. Cancer screening. Cambridge (United Kingdom): Cambridge University Press; 1991. p. 228-39.
7. 7. Bourne TH, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford TJ, et al.The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994;52:379-85.
8. 8. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54: 117-23.
9. 9. Timmerman D, Moerman P, Vergote I. Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Gynecol Oncol 1995;59:405-8.
10. 10. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gyneccol 1990;97:922-9.
11. 11. Valentin L, Sladkevicius P, Marsal K. Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 1994;83:425-33.
12. 12. Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 1996;75:316-29.
13. 13. Bourne TH, Gruböck K, Tailor A. The study of ovarian tumors. In: Bourne TH, Jauniaux E, Jurkovic D, editors. Transvaginal colour Doppler. Berlin: Springer-Verlag; 1995. p. 131-45.
14. 14. Tekay A, Jouppila P. Blood flow in benign ovarian tumors and normal ovaries during the follicular phase. Obstet Gynecol 1995;86:55-9.
15. 15. Declaration of Helsinki: recommendations guiding physicians in biomedical research invoking human subjects. Bull Pan Am Health Organ 1990;24:606-9.
16. 16. Granberg S, Wikland M, Jansson I. Macroscopic characterisation of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989;35:139-44.
17. 17. Annual report on the results of treatment in gynecological cancer. Twenty-first volume. Statements of results obtained in patients treated in 1982 to 1986, inclusive 3 and 5-year survival up to 1990. Int J Gynaecol Obstet 1991;36 Suppl:1-315.
18. 18. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170:81-5.
19. 19. Hanley JA, McNeil B. A method of comparing the areas under the receiver operating characteristics curves derived from the same cases. Radiology 1983;148:839-43.
20. 20. Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynaecol 1997;10:41-7.
21. 21. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian diseases: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-6.
22. 22. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11.